Loading clinical trials...
Loading clinical trials...
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected Treatment-naive Participants. There is a 36 Week, Open-label, Extension Phase for Eligible Participants.
Conditions
Interventions
Elvucitabine
Lamivudine
+2 more
Locations
26
United States
Clinical Trial Site
Little Rock, Arkansas, United States
Clinical Trial Site
Long Beach, California, United States
Clinical Trial Site
Los Angeles, California, United States
Clinical Trial Site
Washington D.C., District of Columbia, United States
Clinical Trial Site
Clearwater, Florida, United States
Clinical Trial Site
Fort Myers, Florida, United States
Start Date
May 1, 2006
Primary Completion Date
August 1, 2007
Completion Date
April 1, 2009
Last Updated
August 30, 2023
NCT04142047
NCT06694805
NCT05398185
NCT07428330
NCT07225530
NCT07429864
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions